Sign Out
Clinical features: Hyperphosphataemia may occur when large doses of DBL Potassium Dihydrogen Phosphate Concentrated Injection are given, especially in patients with renal failure. Symptoms associated with hyperphosphataemia include muscle weakness, paraesthesia, convulsions, cardiomyopathy, respiratory failure and haematological abnormalities.
Hyperphosphataemia may in turn lead to hypocalcaemia and to ectopic calcification, which may be severe.
Crystal deposition may occur in important structures including blood vessels of the eye, lung, heart and kidney. Fatal alveolar diffusion block has occurred, the risk being greater if the patient is alkalotic.
Treatment: Treatment of overdosage involves the following measures: immediate cessation of phosphate therapy; correction of serum electrolyte concentrations, especially calcium; general supportive treatment.
